Kouki Harasaki

What’s with All the Bio M&A in 2019?: A Quick Take

Kouki Harasaki, Nate Chang, Frank Chen

Driven by urgent patent cliffs and $150 billion in available capital, the 2019 biopharmaceutical landscape saw major corporations like Bristol-Myers Squibb and Takeda pursue $94 billion in M&A deals to secure platforms in gene therapy and manufacturing. Buyers increasingly favored strategic acquisitions that offer shared R&D infrastructure and supply chain security, while simultaneously utilizing early-stage licensing to mitigate risk before committing to late-stage assets. Startup executives are advised to secure internal champions and negotiate for standalone operational autonomy to align with shifting commercialization models that prioritize long-term value over traditional full integration.